<DOC>
	<DOCNO>NCT00951600</DOCNO>
	<brief_summary>The study conduct open label , balance , randomize , two-treatment , two-period , two-sequence , single- dose , crossover bioavailability study compare oxcarbazepine 300 mg/5mL oral suspension OHM Laboratories ( subsidiary Ranbaxy Pharmaceuticals Inc. ) TrileptalÂ® 300 mg/5mL oral suspension ( contain oxcarbazepine 300 mg/5mL ) Novartis Pharmaceutical Corporation healthy , adult , male , human subject fast condition .</brief_summary>
	<brief_title>Bioequivalence Study Oxcarbazepine Oral Suspension 300 mg/5 mL Under Fasting Conditions</brief_title>
	<detailed_description>Following overnight fast least 10 hour , single dose 10 mL oxcarbazepine 300 mg/5 mL oral suspension ( contain oxcarbazepine 300 mg/5rnL ) administer use 10 mL graduate syringe , period study supervision train study personnel , along 240 mL drink water ambient temperature . During course study safety parameter assess vital sign , clinical examination , medical history clinical laboratory safety test ( hematology , biochemical parameter , serology urine analysis ) baseline . Laboratory parameter hematology biochemistry repeat end study . A total forty ( 40 ) subject administer single oral dose test reference formulation 10 mL oxcarbazepine 300 mg/5 mL oral suspension ( contain oxcarbazepine 300 mg/5mL ) accord randomization schedule . Thirty-five ( 35 ) subject complete period study .</detailed_description>
	<mesh_term>Oxcarbazepine</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<criteria>1 . Were age range 1845 year . 2 . Were neither overweight underweight correspond height per Life Insurance Corporation India height/weight chart nonmedical case . 3 . Had voluntarily give write informed consent participate study 4 . Were normal health determine medical history physical examination subject perform within 21 day prior commencement study . There deviation regard . 1 . History hypersensitivity oxcarbazepine , carbamazepine relate drug . 2 . History hyponatremia , diplopia . 3 . Recent history dizziness , somnolence , abdominal pain . 4 . Any evidence organ dysfunction clinically significant deviation normal , physical clinical determination . 5 . Presence disease marker HIV 1 2 , Hepatitis B C viruses syphilis infection . 6 . Presence value significantly different normal reference range and/or judge clinically significant hemoglobin , total white blood cell count , differential WBC count platelet count . 7 . Positive urinary screen test drug abuse ( opiates cannabinoids ) . 8 . Presence value significantly different normal reference range and/or judge clinically significant serum creatinine , blood urea nitrogen , serum aspartate aminotransferase ( AST ) , serum alanine aminotransferase ( ALT ) , serum alkaline phosphatase , serum bilirubin , plasma glucose serum cholesterol . 9 . Clinically abnormal chemical microscopic examination urine define presence RBC , WBC ( &gt; 4/HPF ) , glucose ( positive ) protein ( positive ) . 10 . Clinically abnormal ECG Chest Xray . 11 . History serious gastrointestinal , hepatic , renal , cardiovascular , pulmonary , neurological hematological disease , diabetes glaucoma . 12 . History psychiatric illness , might impair ability provide write informed consent . 13 . Regular smoker smoke 10 cigarette daily difficulty abstain smoke duration study period . 14 . History drug dependence excessive alcohol intake habitual basis 2 unit alcoholic beverage per day ( 1 unit equivalent half pint beer I glass wine 1 measure spirit ) difficulty abstain duration study period . 15 . Use enzyme modifying drug within 30 day prior Day 1 study . 16 . Participation clinical trial within 12 week precede Day 1 study . 17 . Subjects , completion study , donate and/or lose 350 mL blood past 3 month . There deviation regard .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Oxcarbazepine oral suspension fasting study</keyword>
</DOC>